LICENSE AGREEMENTS (Details) - USD ($)		6 Months Ended
	Apr. 06, 2016	Jun. 30, 2020
License Agreement [Line Items]
Initial Contribution Received In Related To Joint Venture		$ 3,000,000
Initial Equity Stake		51.00%
Additional Proceeds From License Fees Received		$ 1,000,000
Description of Equity Ownership Interest		RegeneRx's ownership interest in ReGenTree was reduced to 38.5% when the Clinical Study Report was filed for the Phase 2/3 dry eye clinical trial. Based on when, and if, certain additional development milestones are achieved in the U.S. with RGN-259, our equity ownership may be incrementally reduced to between 38.5% and 25%, with 25% being the final equity ownership upon approval of an NDA for DES in the U.S. In addition to our equity ownership, RegeneRx retains a royalty on net sales that varies between single and low double digits, depending on whether commercial sales are made by ReGenTree or a licensee. In the event ReGenTree is acquired or there is a change of control that occurs following achievement of an NDA, RegeneRx shall be entitled to a minimum of 40% of all proceeds paid or payable and will forgo any future royalties.
Revenue, Judgment		Revenue is being recognized on a straight-line basis over a period of 30 years
RGN-259 Agreement [Member]
License Agreement [Line Items]
Milestone Payments		$ 3,500,000
RGN-137 Agreement [Member]
License Agreement [Line Items]
Milestone Payments		$ 3,500,000
Minimum [Member]
License Agreement [Line Items]
Capitalized Contract Cost, Amortization Period		23 years
ReGen Tree [Member]
License Agreement [Line Items]
Proceeds from Royalties Received	$ 250,000